Opinion on R&D

Published within

« | ... | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Sanofi/Organon: Arixtra approved despite safety warning

There should be a strong market for Arixtra, which is approximately 50% more effective than the gold standard therapy, Lovenox, at preventing venous thromboembolism in patients undergoing lower-limb orthopedic surgery. However, Arixtra will have to carry a black box warning due to safety concerns. This is likely to hit its rate of uptake.

Published By Datamonitor
12 Dec 2001
CommentWire
CommentWire

Sankyo: R&D cuts could damage competitiveness

Published By Datamonitor
01 Aug 2001
CommentWire
CommentWire

Roche: Xeloda gets warning on warfarin interaction

Like many drugs, and some foods, Xeloda interacts negatively with popular anticoagulant warfarin. This may reduce the use of Xeloda in cancer patients requiring anticoagulation. It also highlights the potential of AstraZeneca's new oral anticoagulant, ximelagatran, which is currently undergoing phase III trials and is not associated with the interactions that plague warfarin.

Published By Datamonitor
07 Nov 2001
CommentWire
CommentWire

Roche: T-20 demand will outstrip supply

Roche's new HIV drug, T-20, should launch next year. However, it already seems that producing sufficient quantities of T-20 will be a challenge - particularly before the full-scale production facility for the drug comes online. Roche will need to manage customer expectations carefully in the early stages of T-20's launch, or risk losing confidence.

Published By Datamonitor
06 Aug 2002
CommentWire
CommentWire

Roche: stopping Xenical from slimming down

Published By Datamonitor
10 Oct 2001
Expert View
Expert View

Roche: is there a twist in the tail of Roche's tale of woe?

Roche has become the latest pharmaceutical company to report poor financial results. Unlike Eli Lilly and Bristol-Myers Squibb it is not generic competition that has afflicted its profits but a suffering vitamin and fine chemicals division so will the Swiss pharma be able to turn its fortunes around? Datamonitor's Helen Smith and Jonathan Angell take a look.

Published By Datamonitor
11 Mar 2002
CommentWire
CommentWire

Roche: hoping for a better 2002

Much of the fall was due to the troubled vitamin and fine chemicals division, which Roche may well sell this year. However, the pharmaceutical division also had problems. Things may be better 2002, within the cardiovascular sphere at least. If weight loss drug Xenical is approved in type 2 diabetics, the market potential will be considerable.

Published By Datamonitor
01 Mar 2002
CommentWire
CommentWire

Roche: HIV announcement to dispel pipeline fears

Published By Datamonitor
21 Aug 2001
CommentWire
CommentWire

Roche/Schering-Plough: interferon therapy shows potential

According to French research, certain types of B cell lymphoma respond to the hepatitis C immunotherapy, interferon alfa. While this isn't the first time HCV has been linked with lymphoma, the results should still persuade makers of interferon alfa drugs, such as Roche and Schering-Plough to investigate usage in this indication.

Published By Datamonitor
15 Jul 2002
CommentWire
CommentWire

Roche/Genentech: there's no stopping rituximab

According to new studies, Roche and Genentech's anticancer drug rituximab - marketed in the US as Rituxan and in Europe as MabThera - can prolong remission periods in NHL. The findings should increase rituximab's market potential still further, taking it to blockbuster status by next year. The drug may also prove successful in new indications.

Published By Datamonitor
17 Jun 2002

« | ... | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | ... | » »|

No help is available.